HeartSciences Inc.は、MyoVista® wavECGデバイスに対してFDAの510(k)クリアランスを取得し、病院や医療機関での12リード安静心電図の使用が可能になりました。このクリアランスにはAI-ECGアルゴリズムは含まれていません。会社は商業化の選択肢を評価する計画です。
なぜ重要か. HeartSciencesのデバイスは現在、臨床環境で使用可能となり、ECGワークフローの改善と臨床的判断の向上に寄与する可能性があります。
the recoverability of the related inventory
HeartSciences’ amended preliminary proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 6, 2026, in connection with the Proposed Transaction (the “Preliminary Proxy Statement”)
HeartSciences is a healthcare information technology company advancing the use of ECG/EKGs through the integration of artificial intelligence.
HeartSciences’ MyoVista Insights™ Platform is a cloud-native, vendor- and device-agnostic ECG management system designed to modernize ECG workflows and improve clinical efficiency and decision-making.
The proposed business combination with Fortitude Mining Holdings, Inc. (“Fortitude”), announced in June 2026 (the “Proposed Transaction”), continues to progress.
As previously reported, HeartSciences separated the FDA submissions for the MyoVista wavECG device and its impaired cardiac relaxation AI-ECG algorithm following updated guidance published by the American Society of Echocardiography regarding the assessment of left ventricular d…
Food and Drug Administration (“FDA”) has granted 510(k) clearance (K260005) for its MyoVista® wavECGTM device as a 12-lead resting electrocardiograph. The clearance covers the acquisition and interpretation of ECG signals from adult and pediatric patients in hospitals and health…
